Most studies on multiple primaries report on patients seen at certain intervals based on the year of initial cancer diagnosis, while others report on groups of patients seen at a specific period of time, irrespective of the date of initial cancer diagnosis.
This was revealed by multiple primary care based studies [ 26, 27].
Relative survival was calculated and multiple primary tumours were studied.
After exclusion of syndrome-associated and radiation-induced sarcomas, we studied multiple primary malignancies in a population-based cohort of 818 patients with primary STS of the extremities and the trunk wall.
More weight is assigned to primary studies with multiple estimates than to studies with one or two estimates.
Many studies evaluated multiple primary prevention interventions, and some targeted multiple risk factors.
Taking further into account other factors, among them the multiple primary and secondary pharmacodynamic preclinical studies, the risk-benefit analysis is assumed to have a favorable result for the patient population selected.
This table indicates that many included reviews performed multiple meta-analyses with varying numbers of data observations derived from primary studies, possibly reflecting multiple outcomes or subgroup analyses.
The symbiotic architecture called cognitive relaying with frequency incentive for multiple primary users (CRFI-M) was studied by Nadkar et al. [18].
Haraguchi et al. [ 21] demonstrated in their study that multiple primary lung cancers tended to be inherited in family; lung cancer patients with family history had higher chance for a second or third primary tumor than those without family history.
